Carlo brings over three decades of experience in the biopharmaceutical industry both in drug development/licensing and in product launches. He held several positions of increasing scope and responsibility at Genzyme Corporation, the company which pioneered the development of therapeutics for rare diseases. In the beginning, he worked at the European Headquarters in the Netherlands, then at the Corporate Headquarters in the US as Senior Vice President of Global Market Access and later as Chief Medical Officer and Head of Global Medical Affairs.
Carlo is an Operating Partner at Forbion Capital Partners, Naarden, The Netherlands, he is Chairman of the Board at Inversago Pharma, a Canadian company developing CB 1 inverse agonists for metabolic disorders and is also Chairman of the Board at Azafaros B.V., a Dutch company active in lysosomal storage disorders with small molecule inhibitors.
Most recently Carlo was Chairman of the Board of Molmed S.p.a, a public Italian company active in cell and gene therapy, which was sold in July to the Japanese company AGC. Carlo for many years has been a member of the Board of EuropaBio, serving as its Chairman for four years and is a founding member of the International Rare Diseases Research Consortium.
Prior to joining the industry, Carlo was an Associate Professor of Endocrinology at the University of Modena, with a main research focus on thyroid diseases and sex hormones. He received his medical degree at the University of Modena and Reggio Emilia.